Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities

(2017) An-Liang Xia et al.   Oncotarget

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

(2016) Praveen K. Bommareddy et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma

(2016) K. A. Lawson et al.   CLINICAL CANCER RESEARCH

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells

(2016) Justyna Sosna et al.   MOLECULAR AND CELLULAR BIOLOGY

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma

(2016) Anne M Noonan et al.   MOLECULAR THERAPY

Oncolytic viruses as immunotherapy: progress and remaining challenges

(2016) Laure Aurelian   OncoTargets and Therapy

Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis

(2016) Michelle J. Wilkinson et al.   Oncotarget

A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802

(2015) Robert S. DiPaola et al.   EUROPEAN UROLOGY

Immunological Effects of a Tumor Necrosis Factor Alpha–Armed Oncolytic Adenovirus

(2015) Mari Hirvinen et al.   HUMAN GENE THERAPY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment

(2015) Robert HI Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors

(2014) N. Nishio et al.   CANCER RESEARCH

Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer

(2014) A. L. Angelova et al.   JOURNAL OF VIROLOGY

A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses

(2014) James M Markert et al.   MOLECULAR THERAPY

ICAM-1 as a molecular target for triple negative breast cancer

(2014) P. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncolytic Viruses and Their Application to Cancer Immunotherapy

(2014) E. A. Chiocca et al.   Cancer Immunology Research

TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation

(2012) S Jouan-Lanhouet et al.   CELL DEATH AND DIFFERENTIATION

Molecular Pathways: Rodent Parvoviruses--Mechanisms of Oncolysis and Prospects for Clinical Cancer Treatment

(2012) J. P. F. Nuesch et al.   CLINICAL CANCER RESEARCH

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

(2012) James M. Burke et al.   JOURNAL OF UROLOGY

Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

(2012) Evanthia Galanis et al.   MOLECULAR THERAPY

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent

(2011) Svitlana P. Grekova et al.   CANCER BIOLOGY & THERAPY

Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

(2011) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells

(2011) M. Mansour et al.   JOURNAL OF VIROLOGY

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

(2011) Kelley A Parato et al.   MOLECULAR THERAPY

A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers

(2010) Jianhua Chang et al.   CANCER BIOLOGY & THERAPY

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

(2010) Howard L Kaufman et al.   Future Oncology

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

(2009) E. K. Mader et al.   CLINICAL CANCER RESEARCH

Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells

(2009) M. Carlsten et al.   JOURNAL OF IMMUNOLOGY

Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy

(2009) Candice Willmon et al.   MOLECULAR THERAPY

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

(2008) J. L. Gulley et al.   CLINICAL CANCER RESEARCH

Oncolytic viruses: a novel form of immunotherapy

(2008) Robin J Prestwich et al.   Expert Review of Anticancer Therapy

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

(2008) J-L Li et al.   GENE THERAPY

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY

Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM

(2008) James M Markert et al.   MOLECULAR THERAPY

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

(2008) Roberto Cattaneo et al.   NATURE REVIEWS MICROBIOLOGY